NEW YORK (GenomeWeb) – Guardant Health said today that it has signed a deal with Northwestern University making Guardant360 the preferred liquid biopsy test for patients with advanced cancer treated at Northwestern's Robert H. Lurie Comprehensive Cancer Center.

Guardant said that the agreement also covers multiple large-scale prospective clinical trials in which researchers at the Lurie center will use its technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

Researchers link genetic links between education and smoking and longevity.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.